I-Mab (IMAB) Twitter Followers Statistics 2024

296 0.7%

1W 0% 1M 0.3% 3M 4.6%

Followers on Twitter.

Similar companies

Company		Twitter Followers
	Amgen AMGN	121,147 0%
	Gilead Sciences GILD	73,498 0%
	Catalyst Pharmaceuticals CPRX	919 1%
	Inovio Pharmaceuticals INO	17,360 0.1%
	Anavex Life Sciences AVXL	2,022 0%

Month over Month

Followers on Twitter.

Oct 2024	298	4.9%
Sep 2024	284	0%
Aug 2024	284	1.1%
Jul 2024	281

How many users are following I-Mab on Twitter?

I-Mab has 296 followers on Twitter.

Analyzing Twitter Followers, how is I-Mab performing compared to its industry peers?

I-Mab underperforms its industry peers when it comes to Twitter Followers, ranking dead last.

Why should an investor in I-Mab track and monitor Twitter Followers?

Tracking I-Mab's Twitter followers offers insights into its brand popularity and customer engagement. A growing follower count signals rising interest in I-Mab's products, services and a positive brand image. This metric serves as both a measure of engagement and a crucial audience for marketing strategies. By comparing I-Mab's Twitter following with competitors, we gain perspective on its market standing. Although a singular aspect, Twitter followership, when combined with financial and operational data, contributes to a comprehensive understanding of I-Mab's overall performance.

How does the current number of Twitter followers impact I-Mab's brand presence and market influence?

With fewer than 1,000 followers, I-Mab's Twitter account is in its growth phase, focusing on building its audience. This suggests a niche but potentially dedicated following, important for targeted engagement.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.